MX2020005342A - Compuestos de pirazolopiridinona. - Google Patents

Compuestos de pirazolopiridinona.

Info

Publication number
MX2020005342A
MX2020005342A MX2020005342A MX2020005342A MX2020005342A MX 2020005342 A MX2020005342 A MX 2020005342A MX 2020005342 A MX2020005342 A MX 2020005342A MX 2020005342 A MX2020005342 A MX 2020005342A MX 2020005342 A MX2020005342 A MX 2020005342A
Authority
MX
Mexico
Prior art keywords
compounds
pyrazolopyridinone
pyrazolopyridinone compounds
fgfr
inhibitors
Prior art date
Application number
MX2020005342A
Other languages
English (en)
Inventor
Qian Liu
Zhao-Kui Wan
Luoheng Qin
Haibing Guo
Wing Shun Cheung
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2020005342A publication Critical patent/MX2020005342A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)

Abstract

La invención se refiere a nuevos compuestos de pirazolopiridinona, a composiciones farmacéuticas que comprenden dichos compuestos, a procesos para la preparación de dichos compuestos y al uso de dichos compuestos como inhibidores de FGFR (receptor del factor de crecimiento fibroblástico) y a su uso en el tratamiento de enfermedades, por ejemplo, el cáncer.
MX2020005342A 2017-11-24 2018-11-23 Compuestos de pirazolopiridinona. MX2020005342A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2017112836 2017-11-24
PCT/CN2018/117296 WO2019101183A1 (en) 2017-11-24 2018-11-23 Pyrazolopyridinone compounds

Publications (1)

Publication Number Publication Date
MX2020005342A true MX2020005342A (es) 2020-10-14

Family

ID=66630494

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005342A MX2020005342A (es) 2017-11-24 2018-11-23 Compuestos de pirazolopiridinona.

Country Status (12)

Country Link
US (2) US11384099B2 (es)
EP (1) EP3717483B1 (es)
JP (1) JP7329510B2 (es)
KR (1) KR102723359B1 (es)
CN (1) CN111655689B (es)
AU (1) AU2018370904B2 (es)
BR (1) BR112020010004A2 (es)
CA (1) CA3084528A1 (es)
ES (1) ES2963339T3 (es)
MA (1) MA51221A (es)
MX (1) MX2020005342A (es)
WO (1) WO2019101183A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020010012A2 (pt) * 2017-11-24 2020-10-13 Janssen Pharmaceutica Nv compostos de pirazolopiridinona
US12398155B2 (en) 2018-12-26 2025-08-26 Janssen Pharmaceutica Nv Thienopyridinone compounds
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CN111454214B (zh) * 2020-05-27 2023-04-07 龙曦宁（上海）医药科技有限公司 一种2-甲氧基1-嘧啶乙胺盐酸盐的合成方法
WO2022188823A1 (zh) * 2021-03-10 2022-09-15 山东轩竹医药科技有限公司 三并环类hpk1抑制剂及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221683A (en) 1984-03-19 1993-06-22 The Rockefeller University Diaminopyridine compounds and methods of use
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
AUPQ969800A0 (en) 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
JP4341949B2 (ja) * 2000-09-01 2009-10-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アザ複素環式誘導体およびその治療的使用
BRPI0113757B8 (pt) 2000-09-11 2017-11-07 Chiron Corp derivados de quinolinona como inibidores de tirosina quinase
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
JP3539424B2 (ja) * 2002-07-24 2004-07-07 日産自動車株式会社 電気自動車の制御装置
EP2573079A3 (en) * 2002-08-23 2015-03-11 Novartis AG Benzimidazole quinolinones and uses thereof
SG148864A1 (en) 2002-11-13 2009-01-29 Chiron Corp Methods of treating cancer and related methods
JP4823914B2 (ja) 2003-11-07 2011-11-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｆｇｆｒ３の阻害および多発性骨髄腫の治療
JP5760085B2 (ja) 2010-08-04 2015-08-05 武田薬品工業株式会社 縮合複素環化合物

Also Published As

Publication number Publication date
EP3717483A4 (en) 2021-07-14
RU2020120796A (ru) 2021-12-24
EP3717483A1 (en) 2020-10-07
CN111655689B (zh) 2023-01-06
EP3717483B1 (en) 2023-09-06
KR20200090828A (ko) 2020-07-29
US11384099B2 (en) 2022-07-12
WO2019101183A1 (en) 2019-05-31
JP2021504332A (ja) 2021-02-15
AU2018370904B2 (en) 2023-09-21
CN111655689A (zh) 2020-09-11
JP7329510B2 (ja) 2023-08-18
KR102723359B1 (ko) 2024-10-28
ES2963339T3 (es) 2024-03-26
AU2018370904A1 (en) 2020-05-14
BR112020010004A2 (pt) 2020-10-13
US20210147446A1 (en) 2021-05-20
MA51221A (fr) 2020-10-07
US20220340598A1 (en) 2022-10-27
CA3084528A1 (en) 2019-05-31

Similar Documents

Publication Publication Date Title
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX383140B (es) Heterociclos bicíclicos como inhibidores de receptor del factor de crecimiento de fibroblastos (fgfr4).
MX2020014245A (es) Inhibidores de quinasas dependientes de ciclinas.
JOP20180039A1 (ar) مثبطات pd-1/pd-l1
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
JO3512B1 (ar) مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
MY199705A (en) Heterocyclic compounds as immunomodulators
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX393494B (es) Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
PH12018500284A1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
NZ731789A (en) Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
MX373150B (es) Combinaciones de un inhibidor del factor de crecimiento de fibroblasto (fgfr) y un inhibidor del receptor del factor de crecimiento 1 similar a insulina (igf1r).
MX2016005297A (es) Inhibidores del receptor del factor de crecimiento de fibroblastos.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX2020005344A (es) Compuestos de pirazolopiridinona.
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
MX2016014436A (es) Derivados de heterociclil-butanamida.
MX2018003563A (es) Nuevos compuestos.
IN2014MU00303A (es)
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
MX2018005515A (es) Derivados de 1,4-dicarbonil-piperidilo.
MX2020000135A (es) Nuevos compuestos de quinolinona.
JOP20220107A1 (ar) مثبطات egfr تفارغية وطرق استخدامها